MA41985B1 - Composition pour le nettoyage du côlon et le traitement de troubles gastro-intestinaux - Google Patents

Composition pour le nettoyage du côlon et le traitement de troubles gastro-intestinaux

Info

Publication number
MA41985B1
MA41985B1 MA41985A MA41985A MA41985B1 MA 41985 B1 MA41985 B1 MA 41985B1 MA 41985 A MA41985 A MA 41985A MA 41985 A MA41985 A MA 41985A MA 41985 B1 MA41985 B1 MA 41985B1
Authority
MA
Morocco
Prior art keywords
gastrointestinal disorders
cleansing
colon
composition
treating gastrointestinal
Prior art date
Application number
MA41985A
Other languages
English (en)
French (fr)
Other versions
MA41985A (fr
Inventor
Mark Currie
Robert Solinga
Christopher Leitheiser
Original Assignee
Ironwood Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ironwood Pharmaceuticals Inc filed Critical Ironwood Pharmaceuticals Inc
Publication of MA41985A publication Critical patent/MA41985A/fr
Publication of MA41985B1 publication Critical patent/MA41985B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA41985A 2015-05-01 2016-04-29 Composition pour le nettoyage du côlon et le traitement de troubles gastro-intestinaux MA41985B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562156077P 2015-05-01 2015-05-01
PCT/US2016/030061 WO2016178979A1 (en) 2015-05-01 2016-04-29 Compositions for colon cleansing and the treatment of gastrointestinal disorders

Publications (2)

Publication Number Publication Date
MA41985A MA41985A (fr) 2018-03-07
MA41985B1 true MA41985B1 (fr) 2023-04-28

Family

ID=55953439

Family Applications (1)

Application Number Title Priority Date Filing Date
MA41985A MA41985B1 (fr) 2015-05-01 2016-04-29 Composition pour le nettoyage du côlon et le traitement de troubles gastro-intestinaux

Country Status (23)

Country Link
US (2) US10618938B2 (enExample)
EP (2) EP4218789A3 (enExample)
JP (5) JP6930919B2 (enExample)
KR (2) KR20250042844A (enExample)
CN (2) CN114716514A (enExample)
CA (2) CA3172777A1 (enExample)
CY (1) CY1126031T1 (enExample)
DK (1) DK3288578T5 (enExample)
EA (1) EA201792401A1 (enExample)
ES (1) ES2947591T3 (enExample)
FI (1) FI3288578T3 (enExample)
HR (1) HRP20230381T1 (enExample)
HU (1) HUE061954T2 (enExample)
LT (1) LT3288578T (enExample)
MA (1) MA41985B1 (enExample)
MD (1) MD3288578T2 (enExample)
MX (2) MX2017013928A (enExample)
PL (1) PL3288578T3 (enExample)
PT (1) PT3288578T (enExample)
RS (1) RS64160B1 (enExample)
SI (1) SI3288578T1 (enExample)
SM (1) SMT202300114T1 (enExample)
WO (1) WO2016178979A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10618938B2 (en) * 2015-05-01 2020-04-14 Ironwood Pharmaceuticals, Inc. Compositions for colon cleansing and the treatment of gastrointestinal disorders
SI3464336T1 (sl) 2016-06-01 2022-06-30 Athira Pharma, Inc. Spojine
CA3238634A1 (en) * 2021-11-24 2023-06-01 Christopher Leitheiser Synthetic process for production of modified gcc receptor agonists
WO2023097210A1 (en) * 2021-11-24 2023-06-01 Ironwood Pharmaceuticals, Inc. Synthetic process for production of modified gcc receptor agonists
EP4440595A1 (en) * 2021-11-29 2024-10-09 Ironwood Pharmaceuticals, Inc. Pharmaceutical compositions for the treatment of visceral pain
WO2026050206A1 (en) * 2024-08-27 2026-03-05 Ironwood Pharmaceuticals, Inc. Combinations of glp-1 and guanylate cyclase c (gc-c) receptor agonists

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH689139A5 (de) 1995-04-03 1998-10-30 Cerbios Pharma Sa Verfahren zur Herstellung einer liposomalen, in Wasser dispergierbaren, oral zu verabreichenden, festen, trockenen therapeutischen Formulierung.
US5912014A (en) 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
BR122018074353B8 (pt) * 2003-01-28 2023-05-02 Ironwood Pharmaceuticals Inc composição farmacêutica, polipeptídeo e métodos para a produção dos mesmos
US7494979B2 (en) * 2003-06-13 2009-02-24 Ironwood Pharmaceuticals, Inc. Method for treating congestive heart failure and other disorders
EP1940441A4 (en) * 2005-08-19 2010-01-27 Ironwood Pharmaceuticals Inc COMPOSITIONS AND METHODS FOR TREATING GASTROINTESTINAL DISORDERS
US20110172126A1 (en) * 2008-09-03 2011-07-14 Xenome Ltd Libraries of peptide conjugates and methods for making them
CA2790213A1 (en) * 2010-02-17 2011-08-25 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
MX357121B (es) * 2011-03-01 2018-06-27 Synergy Pharmaceuticals Inc Star Proceso de preparacion de agonistas c de guanilato ciclasa.
EP2958577A2 (en) * 2013-02-25 2015-12-30 Synergy Pharmaceuticals Inc. Guanylate cyclase receptor agonists for use in colonic cleansing
PL3004138T3 (pl) * 2013-06-05 2024-07-29 Bausch Health Ireland Limited Ultra-oczyszczeni agoniści peptydowi cyklazy guanylanowej C, sposób ich uzyskiwania i ich zastosowanie
WO2016015055A1 (en) 2014-07-25 2016-01-28 Ironwood Pharmaceuticals, Inc. Colon cleansing compositions
US10618938B2 (en) 2015-05-01 2020-04-14 Ironwood Pharmaceuticals, Inc. Compositions for colon cleansing and the treatment of gastrointestinal disorders

Also Published As

Publication number Publication date
MD3288578T2 (ro) 2023-08-31
RS64160B1 (sr) 2023-05-31
SMT202300114T1 (it) 2023-05-12
US10618938B2 (en) 2020-04-14
CY1126031T1 (el) 2023-11-15
JP7862355B2 (ja) 2026-05-19
CN114716514A (zh) 2022-07-08
FI3288578T3 (fi) 2023-05-03
EP3288578A1 (en) 2018-03-07
EP3288578B8 (en) 2023-03-29
US20180148476A1 (en) 2018-05-31
EP3288578B1 (en) 2023-03-15
JP2025169325A (ja) 2025-11-12
EP4218789A2 (en) 2023-08-02
CA2984437A1 (en) 2016-11-10
EP4218789A3 (en) 2023-09-27
CN108040482B (zh) 2022-03-29
PT3288578T (pt) 2023-03-28
WO2016178979A1 (en) 2016-11-10
LT3288578T (lt) 2023-04-25
CA3172777A1 (en) 2016-11-10
KR20250042844A (ko) 2025-03-27
ES2947591T3 (es) 2023-08-11
CA2984437C (en) 2025-11-18
JP2018519254A (ja) 2018-07-19
MX2022013283A (es) 2022-12-13
JP2024015335A (ja) 2024-02-01
JP2020203954A (ja) 2020-12-24
DK3288578T5 (da) 2024-10-07
SI3288578T1 (sl) 2023-07-31
KR20180005675A (ko) 2018-01-16
KR102783759B1 (ko) 2025-03-21
CN108040482A (zh) 2018-05-15
JP2022121734A (ja) 2022-08-19
DK3288578T3 (da) 2023-05-01
HUE061954T2 (hu) 2023-09-28
JP6930919B2 (ja) 2021-09-01
HRP20230381T1 (hr) 2023-07-07
PL3288578T3 (pl) 2023-08-14
EA201792401A1 (ru) 2018-05-31
MA41985A (fr) 2018-03-07
MX2017013928A (es) 2018-01-15
US20240199697A1 (en) 2024-06-20
BR112017023539A2 (pt) 2018-08-14

Similar Documents

Publication Publication Date Title
MX2024008539A (es) Compuestos bifuncionales para degradar la tirosina cinasa de bruton (btk) mediante la trayectoria de ubiquitina proteosoma.
EA201290322A1 (ru) Лечение желудочно-кишечных расстройств
EA201100062A1 (ru) Соединения и способы модулирования рецепторов, связанных с белком g
EA201300471A1 (ru) Замещенные 6-аминоникотинамиды в качестве модуляторов kcnq2/3
EA201170036A1 (ru) Соединения боронатного эфира и его фармацевтические составы
EA200901032A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
EA201390803A1 (ru) Ингибиторы бромодомена и их применение
EP1881823A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF EYE DISEASES
MA44426B1 (fr) Compositions et méthodes pour diminier l'expression de tau
EA200970337A1 (ru) Ингибиторы котранспортера натрий-глюкозы 2 и способы их применения
ATE530540T1 (de) Pyrimidonverbindungen als gsk-3-inhibitoren
EA201071291A3 (ru) Nmda рецепторные антагонисты для лечения нейропсихиатрических расстройств
EA200602062A1 (ru) Амидосоединения и их применение в качестве фармацевтических средств
NO20090157L (no) Tienpyrimidiner anvendelige som modulatorer av ionekanaler
EA201790653A1 (ru) Способ лечения болезни альцгеймера и других расстройств
EA201290860A1 (ru) Лечение ревматоидного артрита комбинацией лаквинимода и метотрексата
MX2022000712A (es) Moduladores de nlrp3.
MA44935A1 (fr) Compositions pharmaceutiques contenant un antagoniste de l'intégrine alpha 4 , utilisée pour le traitement d"affections inflammatoires oculaires
CL2011002766A1 (es) Compuestos derivados de carboxamida, inhibidores de calpaina; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades neurodegenerativas, alzahimer, dolor, entre otras.
ATE472998T1 (de) Kationische liposomale zubereitungen zur behandlung von rheumatoider arthritis
EA202192925A1 (ru) Твердые формы ингибитора glyt1
EA202190057A1 (ru) Солюбилизированные апиразы, способы и применение
ATE527243T1 (de) Calciumkanal-antagonisten vom typ chinazolinon t
EA201171035A1 (ru) Композиции, включающие модуляторы pde4, и способ их применения для лечения, профилактики и сопровождения туберкулеза
BRPI0907220A2 (pt) métodos de tratar distúrbios de perda óssea usando um antagonista de gm-csf